Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-HBV
- Development stage
- Phase 2
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-HBV is a therapeutic vaccine candidate designed to treat chronic hepatitis B infection. It utilizes a modified vaccinia Ankara (MVA) viral vector engineered to express hepatitis B virus (HBV) antigens, specifically the core antigen (HBc) and surface antigen (HBs), separated by a self-cleaving 2A peptide sequence. The vaccine is part of heterologous prime/boost regimens, where it serves as the "boost" following priming with protein-based HBV vaccines. Its mechanism involves stimulating both humoral and cellular immune responses against HBV, aiming to reduce levels of hepatitis B surface antigen in the blood and enhance immune-mediated clearance of infected cells. The vaccine does not replicate in human cells due to its highly attenuated nature, improving its safety profile[1][2][5]. MVA-HBV is being developed for patients with chronic hepatitis B who are already on nucleos(t)ide analog therapy but have not achieved functional cure.
- Other names
- MVA-HBVac
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on MVA-HBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-HBV.